Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease

24 Feb 2025

Abstract excerpt

Nonmyeloablative (NMA) conditioning is being used increasingly with success in matched related donor (MRD) and alternative donor allogeneic hematopoietic cell transplantation (allo-HCT) in individuals with sickle cell disease (SCD). Advantages include decrease toxicity and applicability in patients otherwise unable to tolerate conditioning regimens due to end-organ damage or age. We aimed to add to published data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hematopoietic Stem Cell Transplantation
Share to Hemoglobinopathies and Related Disorders
Share to Renal Transplantation Outcomes and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40010689
DOI: 10.1016/j.jtct.2025.02.021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell DiseasePMID 40010689Read ↗

Nonmyeloablative Pentostatin-Cyclophosphamide Preconditioning Improves Rates of Engraftment in Adults Undergoing Haploidentical HCT for Sickle Cell DiseaseSemantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is nowSemantic proximity Read ↗

Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseSemantic proximity Read ↗

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesSemantic proximity Read ↗

Stem cell transplantation in sickle cell disease: therapeutic potential and challenges facedSemantic proximity Read ↗

Update of hematopoietic cell transplantation for sickle cell diseaseSemantic proximity Read ↗

Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioningSemantic proximity Read ↗

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.Semantic proximity Read ↗

Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficienciesSemantic proximity Read ↗

Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell diseaseSemantic proximity Read ↗

Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and BelgiumSemantic proximity Read ↗

Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South IndiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.